Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular De... (kets worldwide. Using new ideas BayerSch...)

HOME >> MEDICINE >> TECHNOLOGY

Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration

Date:5/7/2008

kets worldwide. Using new ideas, Bayer Schering Pharma aims to make a contribution to medical progress and strives to improve the quality of life. Find more information at http://www.bayerscheringpharma.de.

About Regeneron

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST(TM) (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. Additional information about Regeneron and recent news releases are available on Regeneron's Web site at http://www.regeneron.com.

* (Note: Lucentis(R) is a registered trademark of Genentech, Inc.)

Bayer HealthCare Forward Looking Statement

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at http://www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Regeneron Forward Looking Statement

This news release discusses historical information and includes forward-looking statements about Regeneron and its products, development programs, finances, and business, all of which
'/>"/>

SOURCE Bayer HealthCare
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
4. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
5. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
6. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
7. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Tainted Chinese Food Ingredients First Discovered in 2005
10. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
11. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD

Post Your Comments:

(Date:5/9/2008)... Agency biologists will play key role in nationa...ildlife Conservation Education Specialist, Pennsy...ny the following article are available from the,Ga...us ) by clicking on "Release,#049-08.", HARRISB...nsylvania Game,Commission has found itself on a ne...

(Date:5/9/2008)... TAMPA, Fla., May 9 /PRNewswire-USNewswire/ -- Os...ting condition that affects almost 50,million peop...tion of,cartilage in bone joints. The novel invest...acting oral analgesic, provided significant relief... those treated with,placebo, and with fewer gastro...

(Date:5/9/2008)... Novel Pain Medicine Studied in Patients Followi...re-USNewswire/ -- Many foot-surgery,patients exper...val of a,bunion, one of the most common foot surge...ol provided significant relief for patients who ha...cebo. Treatment with tapentadol,also resulted in p...

(Date:5/9/2008)... SAN DIEGO, May 9 /- Arde...cused on the discovery and development of,small- m...cer and,inflammatory diseases, including gout, tod...Senior Vice President, Finance and Operations and ... will resign from our board of,directors shortly t...

Breaking Medicine Technology:White Nose Syndrome: Is Pennsylvania Next? 2 White Nose Syndrome: Is Pennsylvania Next? 3 White Nose Syndrome: Is Pennsylvania Next? 4 White Nose Syndrome: Is Pennsylvania Next? 5 White Nose Syndrome: Is Pennsylvania Next? 6 Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 2 Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 3 Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 4 Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 5 New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 2 New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 3 New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 4 New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 5 Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 2 Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 3 Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 4 Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 5 Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 6 Mislabled Supplement Spurred Prostate Cancer 3A Report 9777 1 Mislabled Supplement Spurred Prostate Cancer 3A Report 9777 2 Mislabled Supplement Spurred Prostate Cancer 3A Report 9777 3 LogistiCare a Subsidiary of Providence Service Corp Opens Phoenix Call Center to Support Expanding Commercial Client Base 9774 1 LogistiCare a Subsidiary of Providence Service Corp Opens Phoenix Call Center to Support Expanding Commercial Client Base 9774 2 LogistiCare a Subsidiary of Providence Service Corp Opens Phoenix Call Center to Support Expanding Commercial Client Base 9774 3 VNUS Medical Technologies Appoints Peter Osborne as Chief Financial Officer 9769 1 VNUS Medical Technologies Appoints Peter Osborne as Chief Financial Officer 9769 2 Decision Biomarkers Launches System for Faster Easier Quantification of Protein Biomarkers 2657 1 Decision Biomarkers Launches System for Faster Easier Quantification of Protein Biomarkers 2657 2

[0] White Nose Syndrome: Is Pennsylvania Next?[0] Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile [0] New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery [0] Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results

...New Cardiovascular Target from Lexicon,s Genetic,R...Newswire-FirstCall/ --,Lexicon Pharmaceuticals, In...h demonstrating that antibodies directed to a,pote...PTL4),rapidly lower triglycerides and cholesterol...b) targeting ANGPTL4 may have therapeutic,applicat...

..., N.J.--(BUSINESS WIRE)--Jul 3, 2007 - Nymox,Pharm...ed that,further clinical results from the Company,...sia (BPH) will be presented at the New,England Sec...g in,Boston in September. The paper is authored by... clinical trials of NX-107., The Company previousl...

Other Medicine Technology:Lexicon Develops Antibodies That Lower Triglycerides and,Cholesterol as Potential New Therapy for Heart Disease 2 Lexicon Develops Antibodies That Lower Triglycerides and,Cholesterol as Potential New Therapy for Heart Disease 3 Lexicon Develops Antibodies That Lower Triglycerides and,Cholesterol as Potential New Therapy for Heart Disease 4 Lexicon Develops Antibodies That Lower Triglycerides and,Cholesterol as Potential New Therapy for Heart Disease 5 Clinical Data From Nymox BPH Drug To Be Presented at American,Urological Association Meeting 2

Lexicon Develops Antibodies That Lower Triglycerides and,Cholesterol as Potential New Therapy for Heart Disease Clinical Data From Nymox BPH Drug To Be Presented at American,Urological Association Meeting

(Date:5/13/2008)..., May 13 /PRNewswire-FirstCall/ -- United American...ns and provides comprehensive,management services ...nessee, today announced financial results for its ...ues increased 82 percent to $8.3 million for the t... with revenues of $4.6 million for,the third quart...

(Date:5/13/2008)...N VIEW, Calif., May 13 /PRNewswire-FirstCall/ -- I...financial results for the first,quarter of 2008 en...r of 2008 was $11.5 million, an 8.7%,decrease from...of 2007. The,Company,s net loss was $0.9 million o... 2008 compared with a net loss of $4.9 million or ...

(Date:5/13/2008)...o Explore Strategic Alternatives Ongoing; Company ...flex Product Sales Total $2.4 Million ...y 13 /PRNewswire-FirstCall/ -- MiddleBrook,Pharmac...company focused on,developing and commercializing ...ancial and operational results for the quarter end...

(Date:5/13/2008)...ey prevents hospitals that treat the poor from imp...(HealthDay News) -- The quality of care at hospita... called safety-net hospitals, is lagging well behi...ew study finds. , These hospitals, which rely o...r sources, do not have the money to improve the qu...

[0] United American Healthcare Corporation Announces Fiscal 2008 Third Quarter Results [0] IRIDEX Reports First Quarter 2008 Financial Results [0] MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results [0] Quality Lags at Safety-Net Hospitals

...re low in the body and you are on a dieting course...he waist, say researchers. Nutrition scientists fr...nt of Vitamin C in the body has a direct relation ...ar too less vitamin C in the blood stream, it coul...

...cture in the brain, and quite a tongue twister cal...rvine researchers. // It seems as though there is ...om Mars and Women are from Venus! Researchers hav... the portfolio of handling emotionally influenced ...

... reported in Hypertension: Journal of the American...ight at middle age may increase risks of high bloo...l of Public Health and the College of Physicians a...s E. Gangwisch, Ph.D., lead author and post-doctor...

...published by Yale University and the University of...e of two separate areas of the brain light up when...ach image activates both areas of the brain at the...chers though not yet sure, one theory according to...

Other Medicine News:Health News:Vital Facts of Short Term Diets - Catch The Vitamin Behind An Ample Waist! 2 Health News:Studies Show Brain becomes Less Specialized With Age 2

Vital Facts of Short Term Diets - Catch The Vitamin Behind An Ample Waist!Almond Structure in the Brain Intrigues Researchers Hypertension linked to Insufficient Sleep Studies Show Brain becomes Less Specialized With Age

...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...

Medicine Products:

NMR LipoProfile Nitrazepam, Urine Nictonic Acid Ni, Serum

Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular De...(kets worldwide. Using new ideas BayerSch...),Health